Allogeneic CAR-T cells: more than ease of access?

Graham, Charlotte, Jozwik, Agnieszka, Pepper, Andrea and Benjamin, Reuben (2018) Allogeneic CAR-T cells: more than ease of access? Cells, 7 (10). p. 155. ISSN 2073-4409

[img] PDF - Published Version
Available under License Creative Commons Attribution.

Download (616kB)


Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations, including inability to manufacture CAR-T cells from the patient’s own T cells, disease progression and death prior to return of engineered cells. T cell dysfunction is known to occur in cancer patients, and several groups have recently described differences in CAR-T cells generated from chronic lymphocytic leukaemia (CLL) patients compared with those from a healthy donor. This is thought to contribute to the low response rate in this disease group. Healthy donor, gene-edited CAR-T cells which do not require human leucocyte antigen (HLA) matching have the potential to provide an ‘off the shelf’ product, overcoming the manufacturing difficulties of producing CAR-T cells for each individual patient. They may also provide a more functional, potent product for malignancies such as CLL, where T cell dysfunction is common and frequently cannot be fully reversed during the manufacturing process. Here we review the potential benefits and obstacles for healthy donor, allogeneic CAR-T cells.

Item Type: Article
Keywords: CAR-T cells; cancer immunotherapy; gene editing
Schools and Departments: Brighton and Sussex Medical School > Clinical and Experimental Medicine
Research Centres and Groups: Haematology Research Group
Subjects: R Medicine
Depositing User: Gemma Hamilton
Date Deposited: 04 Oct 2018 10:50
Last Modified: 01 Jul 2019 18:31

View download statistics for this item

📧 Request an update